Transcatheter aortic valve replacement in a patient with renal cell carcinoma. A case report Case report

##plugins.themes.bootstrap3.article.sidebar##

PDF (English)


Opublikowane: sty 23, 2020
DOI: https://doi.org/10.24292/01.OR.120210120
Słowa kluczowe:
cardio-oncology, cancer, transcatheter aortic valve replacement

##plugins.themes.bootstrap3.article.main##

Marcel Pina Ciuffo Almeida
Department of Cardio-Oncology of the Cancer Institute of Sao Paulo, University of Sao Paulo
Thalita Barbosa González
Department of Cardio-Oncology of the Cancer Institute of Sao Paulo, University of Sao Paulo
Isabela Bispo Santos da Silva Costa
Department of Cardio-Oncology of the Cancer Institute of Sao Paulo, University of Sao Paulo
Stéphanie Itala Rizk
Department of Cardio-Oncology of the Cancer Institute of Sao Paulo, University of Sao Paulo
Bruna Morhy Borges Leal Assunção
Heart Institute of Sao Paulo, University of Sao Paulo
Henrique Barbosa Ribeiro
Heart Institute of Sao Paulo, University of Sao Paulo
Ludhmila Abrahão Hajjar
1. Department of Cardio-Oncology of the Cancer Institute of Sao Paulo, University of Sao Paulo. 2. Heart Institute of Sao Paulo, University of Sao Paulo

Abstrakt

 The transcatheter aortic valve replacement (TAVR) is an important therapy for symptomatic patients with severe aortic stenosis who have an intermediate or high surgical risk. The profile of patients eligible for this therapy as first choice has changed over the last few years, with increasing indication even for patients who do not have surgical high risk. Severely ill and frail patients, elderly or patients with multiple clinical comorbidities, such as cancer might be considered for TAVR.

Pobrania

Dane pobrania nie są jeszcze dostepne

##plugins.generic.paperbuzz.metrics##

##plugins.generic.paperbuzz.loading##

##plugins.themes.bootstrap3.article.details##

Jak cytować
1.
Ciuffo Almeida MP, González TB, Costa IBS da S, Rizk SI, Assunção BMBL, Ribeiro HB, Hajjar LA. Transcatheter aortic valve replacement in a patient with renal cell carcinoma. A case report. OncoReview [Internet]. 23 styczeń 2020 [cytowane 22 listopad 2024];10(1(37):5-. Dostępne na: https://journalsmededu.pl/index.php/OncoReview/article/view/1075
Numer
Tom 10 Nr 1(37) (2020)
Dział
CARDIO-ONCOLOGY
Creative Commons License

Utwór dostępny jest na licencji Creative Commons Uznanie autorstwa – Użycie niekomercyjne – Bez utworów zależnych 4.0 Międzynarodowe.

Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.

Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)

Bibliografia

1. Schechter M, Balanescu DV, Donisan T et al. An update on the management and outcomes of cancer patients with severe aortic stenosis. Catheter Cardiovasc Interv. 2019; 94(3): 438-45.
2. Schofer N. Transcatheter Aortic Valve Replacement in Oncology Patients: Does it Make Sense? JACC Cardiovasc Interv. 2019; 12(1): 87-9.
3. Berkovitch A, Guetta V, Barbash IM et al. Favorable Short-Term and Long-Term Outcomes Among Patients With Prior History of Malignancy Undergoing Transcatheter Aortic Valve Implantation. J Invasive Cardiol. 2018; 30(3): 105-9.
4. Baumgartner H, Falk V, Bax JJ et al; ESC Scientific Document Group. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2017; 38(36): 2739-91.
5. Mack MJ, Leon MB, Thourani VH et al; PARTNER 3 Investigators. Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients. N Engl J Med. 2019; 380(18): 1695-705.
6. Watanabe Y, Kozuma K, Hioki H et al. Comparison of Results of Transcatheter Aortic Valve Implantation in Patients With Versus Without Active Cancer. Am J Cardiol. 2016; 118(4): 572-7.
7. Landes U, Iakobishvili Z, Vronsky D et al. Transcatheter Aortic Valve Replacement in Oncology Patients With Severe Aortic Stenosis. JACC Cardiovasc Interv. 2019; 12(1): 78-86.
8. Mangner N, Woitek FJ, Haussig S et al. Impact of active cancer disease on the outcome of patients undergoing transcatheter aortic valve replacement. J Interv Cardiol. 2018; 31(2): 188-96.
9. Reardon MJ, Van Mieghem NM, Popma JJ et al; SURTAVI Investigators. Surgical or Transcatheter Aortic Valve Replacement in Intermediate Risk Patients. N Engl J Med. 2017; 376(14): 1321-31.
10. Bourantas CV, Serruys PW. Evolution of transcatheter aortic valve replacement. Circ Res. 2014; 114(6): 1037-51.
11. Nishimura RA , Otto CM, Bonow RO et al. 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2017; 70(2): 252-89.

Inne teksty tego samego autora